Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nidamin is an intravenous amino acid infusion developed by Wonne International. It is formulated as a nutritive infusion of pure crystalline amino acids (including essential and non-essential amino acids such as L-isoleucine, L-leucine, L-lysine, L-methionine, L-threonine, L-phenylalanine, L-tryptophan, L-valine, L-arginine, L-histidine, and L-glycine) with sorbitol or xylitol. Nidamin is indicated for parenteral nutrition to maintain nitrogen balance, support protein synthesis, and promote tissue repair and recovery in patients who are malnourished, critically ill, or undergoing hemodialysis (as intradialytic parenteral nutrition).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nidamin.